Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer
Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 27, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Herzuma (Trastuzumab-pkrb for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
INCHEON, South Korea& JERUSALEM--(BUSINESS WIRE) December 14, 2018 --Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb), a HER2/neu... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2018 Category: Drugs & Pharmacology Source Type: news
KATHERINE Results Back New Adjuvant Standard for HER2+ Breast Cancer
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Charles E. Geyer Jr, MD Source Type: news
Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity? (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
